Sinocare

Sinocare EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinocare (300298.SZ) as of Oct 16, 2026 is 96.63 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 520.66 M CNY — a change of -81.44% (lower).

EBITDA

96.63 MCNY

YoY

-81.44%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinocare is 2025 96.63 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinocare was 2024 520.66 M CNY. It decreases by -81.44% lower compared to the previous year.

The Sinocare EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
351.08 M CNY
Jan 1, 2019
317.40 M CNY
Jan 1, 2020
410.54 M CNY
Jan 1, 2021
205.29 M CNY
Jan 1, 2022
503.97 M CNY
Jan 1, 2023
402.50 M CNY
Jan 1, 2024
520.66 M CNY
Jan 1, 2025
96.63 M CNY
The Sinocare EBITDA history
YEAREBITDAYoY
96.63 MCNY-81.44%
520.66 MCNY+29.36%
402.50 MCNY-20.13%
503.97 MCNY+145.49%
205.29 MCNY-49.99%
410.54 MCNY+29.34%
317.40 MCNY-9.59%
351.08 MCNY+12.88%
311.03 MCNY+288.43%
80.07 MCNY-43.82%
142.53 MCNY-28.71%
199.93 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare Inc, listed on the Shenzhen Stock Exchange under ticker 300298.SZ, operates as a healthcare company headquartered in Changsha, China. The company went public on March 19, 2012, and currently employs 3,756 full-time staff. Sinocare focuses on the development, production, and sale of rapid detection products for chronic diseases, particularly in the field of diabetes management. Its primary offerings include micro blood glucose monitoring systems, such as blood glucose testing devices and associated test strips, as well as mobile blood glucose monitoring instruments. The company also provides diabetes management information systems to support patient care and data tracking. Sinocare distributes its products both domestically within China and internationally under the brand name SANNUO. The company's website is https://www.sinocare.com/. Sinocare's business model centers on providing accessible and reliable diagnostic tools for chronic disease management, with a strong emphasis on diabetes-related products. The company operates within the healthcare sector, specifically targeting the health care industry segment. Its operations are based in Changsha, Hunan Province, and it serves both local and global markets through its branded products. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinocare is 96.63 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinocare changed from 520.66 M CNY to 96.63 M CNY, representing a -81.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sinocare since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sinocare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sinocare

All Key Metrics — Sinocare